샘플 요청 목록

 카트 문의
시장보고서
상품코드
2148462

폐동맥 고혈압(PAH) 시장

Pulmonary Arterial Hypertension (PAH)
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 356 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,938,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,083,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,815,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 폐동맥 고혈압(PAH) 시장은 2032년까지 120억 달러에 달할 것으로 전망됩니다.

2025년 82억 달러로 추정되는 폐동맥 고혈압(PAH) 세계 시장은 2032년까지 120억 달러에 달할 것으로 예상되며, 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 5.5%로 성장할 것으로 전망됩니다. 본 보고서에서 분석 대상으로 다루고 있는 부문 중 하나인 ‘ERAs’ 약물 군은 연평균 성장률(CAGR) 6.5%를 기록하며, 분석 기간이 끝날 때까지 45억 달러에 달할 것으로 예측됩니다. ‘PDE-5 억제제’ 약물 군 부문의 성장률은 분석 기간 동안 연평균 성장률(CAGR) 6.3%를 나타낼 것으로 추정됩니다.

미국 시장은 22억 달러로 추산되는 반면, 중국 시장은 연평균 성장률(CAGR) 9.6%를 나타낼 것으로 예측됩니다.

미국의 폐동맥 고혈압(PAH) 시장은 2025년에 22억 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 규모를 자랑하는 중국의 경우, 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 9.6%를 기록하며 2032년까지 시장 규모가 26억 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 2.5% 및 4.4%를 나타낼 것으로 예측됩니다. 유럽 내에서는 독일이 연평균 성장률(CAGR) 약 3.5%를 나타낼 것으로 예측됩니다.

세계 폐동맥 고혈압(PAH) 시장 - 주요 동향 및 촉진요인 개요

폐동맥 고혈압(PAH)은 진행성 및 높은 사망률을 특징으로 하며, 여전히 심장학 분야에서 큰 과제로 남아 있습니다. 이 중증 질환은 폐혈관계에 영향을 미치며, 폐동맥압 상승, 우심실 부전, 나아가 사망으로 이어질 수 있습니다. PAH는 폐혈관 수축 및 말초 폐동맥의 진행성 폐색을 특징으로 합니다. 그 병인에는 내피 기능 장애, 만성 염증, 평활근 세포 증식, 폐혈관 리모델링 등 여러 요인이 관여하고 있습니다. 이 질환의 복잡성은 저산소증, 흡연 노출, 유전자 변이, 발육 이상과 같은 다양한 병인에 의해 더욱 가중되고 있습니다. 이러한 요인들로 인해, 유럽심장학회(ESC) 및 유럽호흡기학회(ERS)가 정의한 질환의 근본적인 기전과 분류에 대한 깊은 이해를 바탕으로 한 다각적인 치료 접근법이 필요합니다.

PAH의 병리에는 폐동맥의 현저한 리모델링이 포함되며, 혈관벽의 비후와 내피하로의 비정상 세포 축적이 특징입니다. 이로 인해 혈관 내강이 협착되고 혈관이 폐색되면서 폐혈관 저항이 상승하며, 결국 우심부전으로 이어집니다. 유전학 연구를 통해 BMPR2, CAV1, KCNK3 등의 유전자 변이가 PAH의 중요한 요인임이 밝혀졌으며, 이에 따라 질환에 대한 이해가 깊어지고 잠재적인 치료 표적이 부각되었습니다. BNP/NT-proBNP 등의 바이오마커와 사바이빈, TET2와 같은 새로운 바이오마커는 질환의 중증도, 진행 상황 및 치료 반응에 관한 귀중한 인사이트를 제공합니다. 치료 전략은 PAH에 관여하는 특정 분자 경로를 표적으로 삼도록 발전해 왔습니다. 여기에는 프로스타사이클린 유사체, 엔도셀린 수용체 길항제(ERA), 포스포디에스테라제 5(PDE-5) 억제제, 가용성 구아닐산 시클라제 자극제 등이 포함되며, 각각은 혈관 확장 및 항염증 작용에서부터 혈관 리모델링에 이르기까지 질환의 다양한 측면을 다루고 있습니다.

PAH 치료 분야의 성장은 몇 가지 중요한 요인에 의해 주도되고 있습니다. 비침습적 영상 진단(심초음파 검사, MRI, CT 스캔) 등의 진단 기술 발전으로 인해 더 조기적이고 정확한 진단이 가능해졌으며, 이는 효과적인 치료에 있어 매우 중요합니다. 의료 종사자와 환자들 사이에서 인식이 높아지고 선별 검사가 실시됨에 따라 조기 발견과 치료 시작으로 이어지고 있습니다. 유전자 검사 및 바이오마커를 포함한 맞춤형 의료 접근법을 통해 환자 개개인에 더욱 맞춤화된 효과적인 치료가 가능해졌으며, 이로 인해 환자의 복약 순응도와 치료 성과가 향상되고 있습니다. 모바일 헬스 앱이나 웨어러블 기기 등의 디지털 헬스 도구의 도입은 건강 상태를 실시간으로 모니터링하고 치료 계획을 최적화하기 위한 데이터를 제공함으로써, 환자가 자신의 병세를 보다 효과적으로 관리하는 데 도움을 주고 있습니다. 의료 인프라 개선 및 정책 이니셔티브를 통한 치료 접근성 확대, 그리고 연구 기관과 제약 회사의 협력이 새로운 치료법 개발을 가속화하고 있습니다. 마지막으로, 환자 옹호 활동과 지역사회 지원은 환자 인식 제고 및 정책 수립에 있어 매우 중요한 역할을 수행하고 있으며, 이를 통해 첨단 치료법과 더 나은 치료 기준에 대한 수요를 높이고 있습니다. 이러한 요인들이 결합되어 PAH에 대한 이해, 관리 및 치료가 향상되고 있으며, 이는 기술적, 사회적, 경제적 측면을 결합한 통합적인 접근 방식을 반영하고 있습니다.

부문:

약제 분류별(ERA 계열 약물, PDE-5 억제제, 프로스타사이클린 및 프로스타사이클린 유사체, SGC 자극제), 유형별(브랜드 의약품, 제네릭 의약품), 투여 경로별(경구 투여, 정맥 내/피하 투여, 흡입 투여)

주요 기업

  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Gilead Sciences, Inc.
  • Lung Biotechnology PBC
  • Pfizer Inc.
  • United Therapeutics Corporation

해당 분야의 전문가 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다 - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업의 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합합니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.10.28

Global Pulmonary Arterial Hypertension (PAH) Market to Reach US$12.0 Billion by 2032

The global market for Pulmonary Arterial Hypertension (PAH) estimated at US$8.2 Billion in the year 2025, is expected to reach US$12.0 Billion by 2032, growing at a CAGR of 5.5% over the analysis period 2025-2032. ERAs Drug Class, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the PDE-5 Inhibitors Drug Class segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.6% CAGR

The Pulmonary Arterial Hypertension (PAH) market in the U.S. is estimated at US$2.2 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2032 trailing a CAGR of 9.6% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Pulmonary Arterial Hypertension (PAH) Market - Key Trends and Drivers Summarized

Pulmonary arterial hypertension (PAH) remains a formidable challenge in cardiology, characterized by its progressive nature and high mortality rate. This severe condition affects the pulmonary vasculature, leading to increased pulmonary artery pressure, right ventricular failure, and potentially death. PAH is marked by pulmonary vasoconstriction and progressive occlusion of the distal pulmonary arteries. The pathogenesis involves multiple factors including endothelial dysfunction, chronic inflammation, smooth muscle cell proliferation, and pulmonary vascular remodeling. The disease's complexity is further compounded by various etiologies such as hypoxia, tobacco exposure, genetic mutations, and developmental abnormalities. These factors necessitate a multifaceted approach to management, encompassing a deep understanding of the disease's underlying mechanisms and classifications as delineated by the European Society of Cardiology (ESC) and European Respiratory Society (ERS).

The pathology of PAH includes significant remodeling of the pulmonary arteries, characterized by thickening of the vessel walls and accumulation of abnormal cells under the endothelium. This leads to narrowed vascular beds and occluded vessels, escalating pulmonary vascular resistance and culminating in right heart failure. Genetic research has identified mutations in genes like BMPR2, CAV1, and KCNK3 as critical contributors to PAH, enhancing our understanding and highlighting potential therapeutic targets. Biomarkers such as BNP/NT-proBNP and emerging ones like survivin and TET2 provide valuable insights into disease severity, progression, and treatment response. Treatment strategies have evolved to target specific molecular pathways involved in PAH, including prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase stimulators, each addressing different aspects of the disease from vasodilation and anti-inflammatory actions to vascular remodeling.

The growth in the field of PAH treatment is driven by several key factors. Advancements in diagnostic technologies like non-invasive imaging (echocardiograms, MRI, and CT scans) facilitate earlier and more accurate diagnoses, which is crucial for effective intervention. Increased awareness and screening practices among healthcare providers and patients lead to earlier detection and treatment initiation. Personalized medicine approaches, including genetic testing and biomarkers, enable more tailored and effective treatments, enhancing patient adherence and outcomes. The integration of digital health tools such as mobile health apps and wearable devices helps patients manage their condition more effectively by monitoring health in real-time and providing data to refine treatment plans. Expanded access to treatment through improved healthcare infrastructure and policy initiatives, along with collaborations between research institutions and pharmaceutical companies, accelerates the development of new therapies. Lastly, patient advocacy and community support play vital roles in educating patients and influencing policy, thereby increasing demand for advanced treatments and better care standards. These factors collectively enhance the understanding, management, and treatment of PAH, reflecting an integrated approach that combines technological, social, and economic dimensions.

SCOPE OF STUDY:

The report analyzes the Pulmonary Arterial Hypertension (PAH) market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class, SGC Stimulators Drug Class); Type (Branded Type, Generics Type); Administration Route (Oral Administration Route, Intravenous / subcutaneous Administration Route, Inhalational Administration Route)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Gilead Sciences, Inc.
  • Lung Biotechnology PBC
  • Pfizer Inc.
  • United Therapeutics Corporation

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Pulmonary Arterial Hypertension (PAH) - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 23 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Pulmonary Arterial Hypertension
    • Growth of the Geriatric Population and Associated Health Issues
    • Advancements in PAH Diagnostic Technologies
    • Rising Adoption of Targeted PAH Therapies
    • Impact of COVID-19 Pandemic on PAH Treatment and Diagnosis
    • Government Regulations and Standards for PAH Medications
    • Expansion of PAH Treatment Options in Emerging Markets
    • Development of Combination Therapies for PAH
    • Role of PAH Therapies in Improving Patient Quality of Life
    • Market Penetration of PAH Therapies in Various Healthcare Settings
    • Influence of Technological Innovations on PAH Treatment Efficacy
    • Growth of Personalized Medicine in PAH Treatment
    • Challenges Related to PAH Drug Development and Approval
    • Emerging Markets and Growth Opportunities in Developing Regions
    • Future Trends and Innovations in PAH Treatment and Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pulmonary Arterial Hypertension (PAH) Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Pulmonary Arterial Hypertension (PAH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for ERAs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for ERAs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for ERAs Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for PDE-5 Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for PDE-5 Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for PDE-5 Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Prostacyclin & Prostacyclin Analogs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Prostacyclin & Prostacyclin Analogs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Prostacyclin & Prostacyclin Analogs Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for SGC Stimulators Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for SGC Stimulators Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for SGC Stimulators Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Branded Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Branded Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Branded Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Generics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Generics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Generics Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Intravenous / subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Intravenous / subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Intravenous / subcutaneous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Inhalational Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Inhalational Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Inhalational Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 33: USA Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: USA 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 35: USA Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 36: USA Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: USA 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 38: USA Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 39: USA Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: USA 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: Canada Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: Canada 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Canada Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: Canada 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Canada Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: Canada 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • JAPAN
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Japan Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: Japan 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Japan Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Japan 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Japan Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Japan 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • CHINA
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: China Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: China 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 62: China Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: China Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: China 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 65: China Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: China Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: China 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • EUROPE
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • FRANCE
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: France Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: France 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 83: France Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: France Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: France 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 86: France Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: France Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: France 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • GERMANY
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Germany Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Germany 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Germany Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Germany 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Germany Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Germany 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Italy Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Italy 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Italy Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Italy 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Italy Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Italy 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: UK Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: UK 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 110: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: UK Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: UK 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 113: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: UK Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: UK 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Spain Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: Spain 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Spain Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: Spain 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Spain Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Spain 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Russia Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Russia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Russia Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Russia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Russia Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Russia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Rest of Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Rest of Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Rest of Europe 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Australia Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Australia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Australia Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Australia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Australia Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Australia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • INDIA
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: India Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: India 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 167: India Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: India Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: India 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 170: India Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: India Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: India 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: South Korea Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: South Korea 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: South Korea Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: South Korea 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: South Korea Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: South Korea 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 198: Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Argentina Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Argentina 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Argentina Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Argentina 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Argentina Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Argentina 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Brazil Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Brazil 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Brazil Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Brazil 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Brazil Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Brazil 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Mexico Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Mexico 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Mexico Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Mexico 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Mexico Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Mexico 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Rest of Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Rest of Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Latin America 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 246: Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Iran Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Iran 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Iran Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Iran 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Iran Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Iran 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Israel Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Israel 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Israel Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Israel 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Israel Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Israel 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Saudi Arabia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Saudi Arabia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Saudi Arabia 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: UAE Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: UAE 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: UAE Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: UAE 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: UAE Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: UAE 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Rest of Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Rest of Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Rest of Middle East 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032
  • AFRICA
    • Pulmonary Arterial Hypertension (PAH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Africa Historic Review for Pulmonary Arterial Hypertension (PAH) by Drug Class - ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Africa 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Drug Class - Percentage Breakdown of Value Sales for ERAs Drug Class, PDE-5 Inhibitors Drug Class, Prostacyclin & Prostacyclin Analogs Drug Class and SGC Stimulators Drug Class for the Years 2020, 2026 & 2032
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Africa Historic Review for Pulmonary Arterial Hypertension (PAH) by Type - Branded Type and Generics Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Africa 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Type - Percentage Breakdown of Value Sales for Branded Type and Generics Type for the Years 2020, 2026 & 2032
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Africa Historic Review for Pulmonary Arterial Hypertension (PAH) by Administration Route - Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Africa 13-Year Perspective for Pulmonary Arterial Hypertension (PAH) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Intravenous / subcutaneous Administration Route and Inhalational Administration Route for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기